Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06667141RecruitingPhase 1
Study of ACR-2316 for advanced solid tumors
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
Phoenix, ArizonaAges 18 years+ - NCT07112989Recruiting
Building lab models for sarcoma and cancer spread
This study aims to create new laboratory models to better understand sarcomas and cancers that have spread to the bone or lungs. By using donated tumor tissue and blood, researchers hope to learn how these cancers grow and develop, which could lead to better treatments in the future.
BolognaAges Up to 85 years - NCT07317505RecruitingPhase 1
Study of JMT108 for Advanced Solid Tumors
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Huntersville, North CarolinaAges 18 years+ - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+ - NCT07464457Recruiting
Prehabilitation before cancer treatment
This study tests whether exercise and support before cancer surgery or radiation can improve recovery. It is for adults with solid tumors, especially breast cancer, who are scheduled for curative treatment.
Münster, North Rhine-WestphaliaAges 18–65 - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT05842785RecruitingPhase 1/Phase 2
Study drug for hard-to-treat advanced solid cancers or lymphomas
This early-phase study tests TSN222 in people with advanced, hard-to-treat solid tumors or lymphomas. It aims to see whether the drug can shrink tumors or improve outcomes, including in specific cancer types like head and neck cancer and melanoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07552233Recruiting
NK Cell Therapy for Recurrent Brain Tumors
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT05914545RecruitingPhase 1
Early study drug for advanced solid tumors in adults
This Phase 1 trial tests a new experimental medicine (FZ-AD004) in adults with advanced solid tumors. It aims to see how the drug behaves in the body and whether it’s safe enough to continue in patients with measurable cancer.
HangzhouAges 18–75 - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Scottsdale, ArizonaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07222267RecruitingPhase 1
Study of BG-75202 for advanced solid tumors
This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.
Birmingham, AlabamaAges 18 years+ - NCT02555735Enrolling by invitation
Study of exceptional responders with solid tumors on chemotherapy
This study looks at people with solid tumor cancer (like many common carcinomas) to understand who responds exceptionally well to chemotherapy. You might be eligible if you are newly diagnosed or already receiving chemotherapy and can follow the study plan.
Los Angeles, CaliforniaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06378593RecruitingPhase 1/Phase 2
Study of drug 3HP-2827 for tumors with FGFR2 changes
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05608148RecruitingPhase 1
GAIA-102 for relapsed or hard-to-treat childhood cancers
This Phase 1 study tests GAIA-102 in children and young adults whose cancer has returned or not responded to standard treatments. It aims to see if the treatment is safe and whether it may shrink tumors in certain pediatric solid cancers.
Fukuoka, FukuokaAges 1–24 - NCT07015697RecruitingPhase 1
Study of subcutaneous trastuzumab deruxtecan for advanced solid tumors
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT06806982RecruitingPhase 1
Study of VRN101099 for HER2-positive solid tumors
This trial tests a new drug, VRN101099, for people with HER2-positive or HER2-mutated cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow cancer growth.
Darlinghurst, New South WalesAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,689 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.